Heat Shock Protein 90 (Hsp90) is known to be a highly conserved protein amongst these bacterial pathogens and is involved in a variety of morphological processes. Inhibiting Hsp90 is therefore recognized as a potential therapeutic target for the treatment of these pathogens. USF inventors have developed a series of novel Hsp90 inhibitors that they have shown to be effective against Leishmania donovani and ESKAPE pathogens. This development has the potential to provide a new more effective treatment that is also less toxic than the current gold standard treatments.
Heat Shock Protein Inhibitor Compound Docked in Active Site of Hsp90